Logo image of BGBIO.OL

BERGENBIO ASA (BGBIO.OL) Stock Fundamental Analysis

OSL:BGBIO - Euronext Oslo - NO0013251173 - Common Stock - Currency: NOK

1.832  -0.1 (-5.08%)

Fundamental Rating

2

BGBIO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 73 industry peers in the Biotechnology industry. While BGBIO seems to be doing ok healthwise, there are quite some concerns on its profitability. BGBIO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BGBIO has reported negative net income.
In the past year BGBIO has reported a negative cash flow from operations.
BGBIO had negative earnings in each of the past 5 years.
BGBIO had a negative operating cash flow in each of the past 5 years.
BGBIO.OL Yearly Net Income VS EBIT VS OCF VS FCFBGBIO.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

BGBIO has a worse Return On Assets (-89.40%) than 73.97% of its industry peers.
BGBIO has a Return On Equity (-113.51%) which is in line with its industry peers.
Industry RankSector Rank
ROA -89.4%
ROE -113.51%
ROIC N/A
ROA(3y)-126.61%
ROA(5y)-96.68%
ROE(3y)-201.42%
ROE(5y)-144.62%
ROIC(3y)N/A
ROIC(5y)N/A
BGBIO.OL Yearly ROA, ROE, ROICBGBIO.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

BGBIO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BGBIO.OL Yearly Profit, Operating, Gross MarginsBGBIO.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K

More info and screens

5

2. Health

2.1 Basic Checks

BGBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BGBIO has more shares outstanding
The number of shares outstanding for BGBIO has been reduced compared to 5 years ago.
Compared to 1 year ago, BGBIO has a worse debt to assets ratio.
BGBIO.OL Yearly Shares OutstandingBGBIO.OL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
BGBIO.OL Yearly Total Debt VS Total AssetsBGBIO.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -0.69, we must say that BGBIO is in the distress zone and has some risk of bankruptcy.
BGBIO's Altman-Z score of -0.69 is in line compared to the rest of the industry. BGBIO outperforms 46.58% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that BGBIO is not too dependend on debt financing.
BGBIO has a Debt to Equity ratio of 0.01. This is amongst the best in the industry. BGBIO outperforms 86.30% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -0.69
ROIC/WACCN/A
WACC8.5%
BGBIO.OL Yearly LT Debt VS Equity VS FCFBGBIO.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 4.79 indicates that BGBIO has no problem at all paying its short term obligations.
BGBIO's Current ratio of 4.79 is fine compared to the rest of the industry. BGBIO outperforms 78.08% of its industry peers.
A Quick Ratio of 4.79 indicates that BGBIO has no problem at all paying its short term obligations.
The Quick ratio of BGBIO (4.79) is better than 84.93% of its industry peers.
Industry RankSector Rank
Current Ratio 4.79
Quick Ratio 4.79
BGBIO.OL Yearly Current Assets VS Current LiabilitesBGBIO.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for BGBIO have decreased strongly by -125.07% in the last year.
Looking at the last year, BGBIO shows a very strong growth in Revenue. The Revenue has grown by 139.55%.
Measured over the past years, BGBIO shows a very negative growth in Revenue. The Revenue has been decreasing by -37.51% on average per year.
EPS 1Y (TTM)-125.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.5%
Revenue 1Y (TTM)139.55%
Revenue growth 3Y3.09%
Revenue growth 5Y-37.51%
Sales Q2Q%92.37%

3.2 Future

BGBIO is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -15.45% yearly.
BGBIO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 210.58% yearly.
EPS Next Y17.6%
EPS Next 2Y-31.23%
EPS Next 3Y-17.38%
EPS Next 5Y-15.45%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y210.58%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BGBIO.OL Yearly Revenue VS EstimatesBGBIO.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2028 50M 100M 150M 200M 250M
BGBIO.OL Yearly EPS VS EstimatesBGBIO.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -10 -20 -30 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BGBIO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BGBIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BGBIO.OL Price Earnings VS Forward Price EarningsBGBIO.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BGBIO.OL Per share dataBGBIO.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

A cheap valuation may be justified as BGBIO's earnings are expected to decrease with -17.38% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-31.23%
EPS Next 3Y-17.38%

More info and screens

0

5. Dividend

5.1 Amount

BGBIO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BERGENBIO ASA

OSL:BGBIO (5/30/2025, 7:00:00 PM)

1.832

-0.1 (-5.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-21 2025-05-21
Earnings (Next)08-20 2025-08-20
Inst Owners4.19%
Inst Owner ChangeN/A
Ins Owners3.45%
Ins Owner ChangeN/A
Market Cap71.61M
Analysts40
Price Target5.1 (178.38%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)44.67%
Min EPS beat(2)34.98%
Max EPS beat(2)54.35%
EPS beat(4)3
Avg EPS beat(4)33.21%
Min EPS beat(4)-7.96%
Max EPS beat(4)54.35%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-75%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)43.71%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 84.45
P/FCF N/A
P/OCF N/A
P/B 0.58
P/tB 0.58
EV/EBITDA N/A
EPS(TTM)-3.75
EYN/A
EPS(NY)-3.09
Fwd EYN/A
FCF(TTM)-3.92
FCFYN/A
OCF(TTM)-3.92
OCFYN/A
SpS0.02
BVpS3.14
TBVpS3.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -89.4%
ROE -113.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-126.61%
ROA(5y)-96.68%
ROE(3y)-201.42%
ROE(5y)-144.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.79
Quick Ratio 4.79
Altman-Z -0.69
F-Score4
WACC8.5%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-125.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.5%
EPS Next Y17.6%
EPS Next 2Y-31.23%
EPS Next 3Y-17.38%
EPS Next 5Y-15.45%
Revenue 1Y (TTM)139.55%
Revenue growth 3Y3.09%
Revenue growth 5Y-37.51%
Sales Q2Q%92.37%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y210.58%
EBIT growth 1Y21.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year35.54%
EBIT Next 3Y25.86%
EBIT Next 5Y-28.86%
FCF growth 1Y31.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.92%
OCF growth 3YN/A
OCF growth 5YN/A